Back to search

Article

Repurposing FDA-Approved Agents to Develop a Prototype Helicobacter Pylori Shikimate Kinase (HPSK) inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculation, MD Simulations, and DFT Analysis

2024-12-25

Abstract excerpt

<h4>Background: </h4> / Objectives: Helicobacter pylori infects approximately half of the global popu-lation, causing chronic gastritis, peptic ulcers, and gastric cancer, a leading cause of can-cer mortality. While current therapies face challenges from rising antibiotic resistance, particularly to clarithromycin, alongside treatment complexity and costs, the World Health Organization has prioritized the developm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
51f2defb-6329-5a47-baa6-3e85ccbfe1f9
DOI
10.20944/preprints202412.2146.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Repurposing FDA-Approved Agents to Develop a Prototype Helicobacter Pylori Shikimate Kinase (HPSK) inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculation, MD Simulations, and DFT AnalysisDOI 10.20944/preprints202412.2146.v1
Mechanistic inhibition of gastric cancer-associated bacteria Helicobacter pylori by selected phytocompounds: A new cutting-edge computational approachSemantic proximity
Identification of novel drug targets for Helicobacter pylori: structure-based virtual screening of potential inhibitors against DAH7PS protein involved in the shikimate pathwaySemantic proximity
High-throughput screening and molecular dynamics simulations of natural products targeting LuxS/AI-2 system as a novel antibacterial strategy for antibiotic resistance in Helicobacter pyloriSemantic proximity
In Silico exploration for potent phytochemicals targeting Helicobacter pylori: assessment of ADMET profiles and molecular docking analysisSemantic proximity
Integrated computer-aided drug design and biophysical simulation approaches to determine natural anti-bacterial compounds for Acinetobacter baumanniiSemantic proximity
Computational Identification of Natural Product-Derived GSK-3β Inhibitors as Candidate Therapeutics for Type 2 Diabetes and MASHSemantic proximity
Characterization and targeting of deleterious mutations in Carbapenemase-producing Klebsiella pneumoniae: insights from variant calling, Computer-aided drug design, and DFT analysis.Semantic proximity
Old Arsenal to Combat New Enemy: Repurposing of Commercially Available FDA Approved Drugs Against Main Protease of SARS-CoV2.Semantic proximity
Investigation of a set of flavonoid compounds as Helicobacter pylori urease inhibitors: insights from in silico studiesSemantic proximity
Epigallocatechin Gallate with Potent Anti-Helicobacter pylori Activity Binds Efficiently to Its Histone-like DNA Binding ProteinSemantic proximity
Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2Semantic proximity
In silico design and pharmacokinetics investigation of some novel hepatitis C virus NS5B inhibitors: pharmacoinformatics approachSemantic proximity
Select a neighboring publication to make it the new centre.